This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


5zpw

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 5zpw is ON HOLD until Paper Publication
+
==Generation of a long-acting fusion inhibitor against HIV-1==
 +
<StructureSection load='5zpw' size='340' side='right' caption='[[5zpw]], [[Resolution|resolution]] 2.20&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[5zpw]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5ZPW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ZPW FirstGlance]. <br>
 +
</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=MK8:2-METHYL-L-NORLEUCINE'>MK8</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5zpw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5zpw OCA], [http://pdbe.org/5zpw PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5zpw RCSB], [http://www.ebi.ac.uk/pdbsum/5zpw PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5zpw ProSAT]</span></td></tr>
 +
</table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
AIDS has evolved from a fatal infectious disease to a manageable chronic disease under the treatment of anti-AIDS medications. HIV fusion inhibitors with high activity, low side effects and strong selectivity are promising drugs against HIV. Only one fusion inhibitor is currently approved, thereby highly active long-acting fusion inhibitors need to be developed for long-term AIDS treatment. Here, we synthesised MT-SC22EK (a small HIV fusion inhibitor) derivatives containing 1-2 staples to improve its stability. Antiviral activity studies showed that MT-SC22EK-2 with two staples exhibited potent inhibitory activity against HIV-1 standard strains and Chinese epidemic strains, and at the same time, MT-SC22EK-2 presented strong anti-T20 resistance. Surprisingly, MT-SC22EK-2 possessed excellent protease stability with a half-life of 3665 min. MT-SC22EK-2 is a potential HIV fusion inhibitor considered as a long-acting anti-HIV drug candidate.
-
Authors:
+
Generation of a long-acting fusion inhibitor against HIV-1.,Guo Y, Zhou PP, Zhang SY, Fan XW, Dou YW, Shi XL Medchemcomm. 2018 Jun 6;9(7):1226-1231. doi: 10.1039/c8md00124c. eCollection 2018, Jul 1. PMID:30109011<ref>PMID:30109011</ref>
-
Description:
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
 +
<div class="pdbe-citations 5zpw" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Guo, Y]]
 +
[[Category: Shi, X L]]
 +
[[Category: Complex]]
 +
[[Category: Inhibitor]]
 +
[[Category: Virus]]
 +
[[Category: Virus like particle]]

Revision as of 07:23, 6 March 2019

Generation of a long-acting fusion inhibitor against HIV-1

5zpw, resolution 2.20Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/5zpw"
Personal tools